Theorem Clinical Research


Choose a date range

From To

Choose one or more categories


Show only original CenterWatch stories


Array BioPharma purchases phase III assets from Novartis

Wednesday, March 4, 2015 01:07 PM

Array BioPharma has completed both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

More... »

Quest Diagnostics

Bristol-Myers Squibb, Bavarian Nordic ink agreement for PROSTVAC

Wednesday, March 4, 2015 01:06 PM

Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

More... »

Blueprint Medicines, Alexion Pharmaceuticals ink $265M deal

Wednesday, March 4, 2015 12:55 PM

Blueprint Medicines is collaborating with Alexion Pharmaceuticals to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease.

More... »

AstraZeneca, Cambridge Judge Business School collaborate to support biotech startups

Wednesday, March 4, 2015 09:35 AM

AstraZeneca and the University of Cambridge Judge Business School have announced an agreement to deliver a new “Accelerate Cambridge Life Sciences” program at the business school that will identify, train and mentor start-up ventures in the life sciences.

More... »

New patient contact registry for rare eosinophilic gastrointestinal diseases

Wednesday, March 4, 2015 09:01 AM

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) has launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases (EGID), a group of rare diseases. The registry is located at Its purpose is to create a single, international database with information submitted by patients with EGID and their families. The database will enable CEGIR investigators to identify and recruit patients with EGID for new research studies for improving treatments and clinical care.

More... »

CRL announces planned management changes

Wednesday, March 4, 2015 08:50 AM

Massachusetts-based Charles River Laboratories International has announced planned management changes to be implemented over the course of 2015.

More... »

SynteractHCR expands senior management team

Wednesday, March 4, 2015 08:47 AM

San Diego-based CRO SynteractHCR has hired Etienne Drouet as vice president, strategic development. This is a new position created to augment the depth of the company’s oncology and complex trial expertise.

More... »

ERT to acquire PHT

Monday, March 2, 2015 03:38 PM

ERT, a global provider of patient safety and efficacy endpoint data collection, has signed a definitive agreement to acquire PHT, an electronic patient diary solutions provider that helps biopharmaceutical companies collect and manage clinical trial data.

More... »

Akili collaborates with Autism Speaks affiliate DELSIA

Monday, March 2, 2015 03:11 PM

Boston-based Akili Interactive Labs, developing clinically-validated video games for cognitive assessment and personalized treatment, has entered into a clinical collaboration agreement with Delivering Scientific Innovation for Autism (DELSIA).

More... »

Teva to sell Sellersville, Pa., facility to G&W Labs

Monday, March 2, 2015 03:08 PM

Jerusalem-based Teva Pharmaceutical Industries will sell its Sellersville, Pa., facility to G&W Laboratories, as part of a plan to streamline operations by reducing excess manufacturing capacity. It is part of Teva’s previously announced cost reduction program.

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs